Assessment of ovarian function with anti-Müllerian hormone in systemic lupus erythematosus patients undergoing hematopoietic stem cell transplant.
In this small pilot study, anti-Müllerian hormone (AMH) levels in women undergoing chemotherapy and hematopoietic stem cell transplantation facilitated earlier identification of impaired ovarian reserve compared with FSH and the resumption of menses. Larger studies are needed to accurately assess the clinical significance of AMH levels in the prediction of long-term reproductive outcomes in reproductive-age transplant patients with our current conditioning regimen.
Browne
Hyacinth
H
Program in Reproductive and Adult Endocrinology, NICHD, National Institutes of Health, Bethesda, Maryland 20892, USA. brownehy@mail.nih.gov
Armstrong
Alicia
A
Decherney
Alan
A
Babb
Rebecca
R
Illei
Gabor
G
Segars
James
J
Pavletic
Steven
S
D000293:Adolescent; D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000601:surgery; D008598:Menstruation / Q000502:physiology; D010053:Ovary / Q000502:physiology*; D010865:Pilot Projects; D012098:Reproduction / Q000502:physiology; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D055815:Young Adult
D015415:Biomarkers; D004958:Estradiol; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone